Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03023722 · ClinicalTrials.gov registry record · Phase 2
Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT03023722 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 18 participants.
The verdict
NCT03023722, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary objective of this study is to: -Test the activity/response rate per RECIST 1.1 criteria of anetumab ravtansine in patients with advanced pancreatic cancer who stain for mesothelin expression The secondary objectives of this study are to: * Time to Progression (TTP) defined as time from study treatment to RECIST 1.1 progression, or death (others going off study will be censored) * Toxicity in pancreatic cancer patients (at 6.5 mg/kg dose)
Interventions
- DRUG anetumab ravtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-05-11 |
| Est. Completion | 2019-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03023722
The ClinicalTrials.gov registry entry for NCT03023722 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anetumab ravtansine is the first listed.
NCT03023722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03023722 about?
NCT03023722 is a clinical study titled "Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer". The primary objective of this study is to: -Test the activity/response rate per RECIST 1.1 criteria of anetumab ravtansine in patients with advanced pancreatic cancer who stain for mesothelin expression The secondary objectives of this study are to: * Time to Progression (TTP) defined as time fro...
What is the current status of trial NCT03023722?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2017-05-11. Estimated completion is 2019-12-11.
What interventions are being tested in trial NCT03023722?
The interventions under investigation include: anetumab ravtansine (DRUG).
Who is sponsoring clinical trial NCT03023722?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.